curs in combination with obesity and insulin resistance (as it frequently does), there is a marked increase in risk of incident T2DM with possible synergism occurring between liver fat accumulation, insulin resistance and obesity to further increase risk of development of T2DM. Thus, there is a reciprocal relationship between NAFLD as a risk factor for T2DM, and T2DM as a risk factor for liver disease progression in NAFLD. Moreover, recent evidence now points to the importance of perturbation of the intestinal microbiota (dysbiosis) in both T2DM and NAFLD. Consequently, there is a triangular relationship between dysbiosis and T2DM and NAFLD. This review will focus on T2DM as a key extrahepatic complication of NAFLD and will describe and discuss the triangular relationship between dysbiosis and T2DM and NAFLD and the factors and potential mechanisms underpinning this relationship.
with lipid accumulation in the hepatocytes, it can progress to liver inflammation with activation of hepatic stellate cells (non-alcoholic steatohepatitis [NASH] ), subsequently leading to fibrosis with hepatic collagen deposition, and ultimately to hepatocellular carcinoma. The development of hepatic fibrosis occurs in 40-50% of patients with NASH and current estimates are that approximately 30-40% of people with NAFLD develop NASH [1] . There is growing evidence that NAFLD is a multisystem disease, affecting several extrahepatic organs and regulatory pathways. Since NAFLD has become the predominant cause of chronic liver disease in many parts of the world, NAFLD is also potentially contributing to an important burden of extrahepatic chronic complications such as type 2 diabetes mellitus (T2DM) [2, 3] .
NAFLD has a multifactorial pathophysiology involving genetic (PNPLA3 I148M polymorphism) [4] and metabolic factors, such as sedentary lifestyle, increased intake of energy-rich foods, malnutrition characterized by an imbalanced intake of nutrients (e.g., high fat and high proteins diet, low fiber intake, high fructose intake) [5] , altered gut microbiota composition (dysbiosis) [6] , obesity, insulin resistance and T2DM [7] . The interaction between diet, host and gut microbiota can modulate inflammatory signaling pathways that in turn cause obesity, NAFLD and insulin resistance. The number of bacterial cells present in the mammalian gastrointestinal tract increases according to its pH. There are approximately 1 × 10 3 bacteria per gram of contents in the stomach and duodenum where the pH ranges from 1.5 to 4. In the jejunum and ileum, there are approximately 1 × 10 4 -1 × 10 7 bacteria, culminating in the colon (pH 5.5-7) with 1 × 10 11 -1 × 10 12 bacteria [8] . Recent data from animal studies have shown that the gut microbiota contributes to the pathogenesis of NAFLD via multiple mechanisms including regulation of energy homeostasis [9] and metabolic endotoxemia [10] .
Dysbiosis favors the overgrowth of gram-negative bacteria, leading to an increased production of lipopolysaccharide (LPS) from the gram-negative cell walls. Cani et al. [11] have identified LPS as a trigger factor for insulin resistance, obesity and diabetes; they also demonstrated that LPS causes metabolic endotoxemia and inflammation.
This review will describe and discuss the triangular relationship between dysbiosis-T2DM-NAFLD and the factors and potential mechanisms underpinning this relationship ( fig. 1 ).
Gut Dysbiosis and NAFLD
The prevalence of NAFLD in the general population is estimated at 20-30%; however, this prevalence increases up to 75-100% in presence of obesity and T2DM. Currently, one-third of the global population is obese/overweight increasing the risk of developing NAFLD [12] . There are different aspects influencing the etiology of obesity such as genetic, physiological and lifestyle factors.
Recent studies have shown a functional relationship between gut microbiota composition and obesity [13] . The human gut microbiota is characterized by 5 bacterial Phyla (Firmicutes, Bacteroidetes, Actinobacteria and Verrucomicrobia) and one Archaea (Euryarchaeota). There are endogenous (dietary habits, fiber intake, lifestyle and drugs) and exogenous (bacterial mucosal interactions, intestinal pH and immune response) factors that can influence the equilibrium of the gut microbiota [14] .
Several human and animal studies have shown a specific change in the gut microbiota composition in obese people with a reduction in Bacteroidetes phylum and increase in Firmicutes phylum [15, 16] . Ley et al. [17] studied the intestinal microbiota of genetically obese ob/ob mice, lean ob/+ and wild-type siblings fed with the same polysaccharide-rich diet. They showed that the genetically obese mice had a 50% reduction of Bacteroidetes phylum and a proportional increase in Firmicutes phylum compared to lean sibling mice, despite being fed with the same diet. Similar changes in gut microbiota have been found in human studies. Interestingly, Ley et al. [18] showed that the colonization of germ-free mice with an 'obese gut microbiota' results in a significantly greater increase in total body fat than colonization with a 'lean microbiota'. With this study, they showed that obese microbiome (the genomic content of the gut microbiota) had an increased capacity to harvest energy from food and therefore it is an additional contributing factor to the pathophysiology of obesity.
Healthy gut bacteria ferment complex carbohydrates into short-chain fatty acids (SCFAs; primarily acetate, propionate and butyrate) and make them absorbable by the intestinal epithelium [19] . Butyrate is an important energy source for the colonocytes, while acetate and propionate are primarily absorbed and extracted by the liver where they are used as substrates for lipogenesis and gluconeogenesis [20] . SCFAs are necessary for the growth of healthy bacteria, the regulation of intestinal pH and the maintenance of the gut bacteria health equilibrium. All these SCFA functions have beneficial effects on NAFLD [21] . Moreover, SCFA production is important as SCFAs have a strong capacity to downregulate inflammatory processes. SCFAs bind to and stimulate the chemoattractant receptor GPR43 on neutrophils, which is necessary for the resolution of inflammatory responses [22] .
Qin et al. [23] have shown that, in patients with cirrhosis, the composition of the gut microbiota is characterized by low abundance in butyrate-producing bacteria compared with healthy control group subjects, in which there is a 'healthy gene-rich' microbiome. These authors identified several bacteria as part of the 'healthy generich' microbiome, including Faecalibacterium prausnitzii , which has anti-inflammatory properties, and Coprococcus comes , which contributes to gut health through butyrate production [23] . In a different study, Chen et al. [24] used pyrosequencing of the 16S rRNA V3 region and real-time qPCR to characterize the gut microbiota of patients with cirrhosis. They found markedly high levels of several gram-negative bacteria, such as Proteobacteria and Fusobacteria . Similarly, van Best et al. [25] showed that, in patients with NAFLD, Proteobacteria , Enterobacteriaceae (Escherichia) and Ruminococcaceae (Faecalibacterium) were abundant compared with obese and healthy subjects. In a recent study on 57 patients with biopsyproven NAFLD, Boursier et al. [26] identified that Bacteroides were independently associated with NASH and that Ruminococcus are associated with significant fibrosis. In addition, Zhu et al. [27] showed that there are ethanol-producing bacteria, such as E. coli , that are capable of aggravating liver condition. These bacteria constantly produce alcohol and thus continuously supply reactive oxygen species to the liver, causing liver inflammation and NASH.
Dysbiosis and Adipose Tissue Triglyceride Regulation
In presence of high energy intake and low energy expenditure, adipose tissue is overloaded by an excess of energy stored as lipid (triacylglycerol). The ability of expansion of the peripheral adipose tissue provides a temporary buffering capacity that protects the liver from an excessive flux of free fatty acid (FFA), which would otherwise promote hepatic lipid accumulation. If this protective mechanism fails, excessive FFA causes hepatic/peripheral insulin resistance, hepatic inflammation and in turn increases the risk of progressive liver disease with fibrosis, cirrhosis and hepatocellular carcinoma [28] .
As a consequence of dysbiosis, gut microbiota can suppress the intestinal epithelial expression of the fastinginduced adipose factor, also known as angiopoietin-like protein-4 (ANGPTL4), which is an inhibitor of circulating lipoprotein lipase (LPL) [14] . ANGPTL4 is a protein secreted by the liver and adipose tissue and plays an important role in lipid metabolism and glucose homeostasis. LPL is the main rate-limiting enzyme in the lipid metabolism pathway. It primarily catalyzes the hydrolysis of triglycerides into FFAs and monoacylglycerol [29] .
Reduced level of ANGPTL4 fails to inhibit LPL activity, and therefore, there is an increase in FFA flux from the adipose tissue to the liver that increases the availability of long-chain fatty acyl-CoAs for hepatic lipid accumulation. LPL overexpression in the liver has been associated with liver triglyceride accumulation and NAFLD [30] .
Consistently, a mouse study has showed that supplementation with probiotic bacteria Lactobacillus paracasei was associated with a beneficial effect on ANGPTL4, inhibiting LPL activity and improving lipid metabolism [31] .
A further effect of gut microbiota on lipid metabolism concerns the regulation of dietary choline in the intestine. Choline is an essential nutrient and it is mostly obtained from food such as red meat and eggs. Choline is essential for neurotransmitter synthesis, methyl group metabolism, cell membrane structure and signaling, lipid metabolism and synthesis of very low-density lipoprotein in the liver [32] . Moreover, choline is metabolized in the liv- er to phosphatidylcholine, which is necessary for the packaging and export of triglycerides in very low-density lipoproteins. The conversion of dietary choline to methylamines by gut dysbiosis reduces the bioavailability of choline in the intestine and mimics the effect of cholinedeficient diets, causing a predisposition to impaired glucose homeostasis [33] .
Gut Dysbiosis, NAFLD and T2DM
Recent evidence shows that gut dysbiosis also plays a key role in the pathogenesis and progression of NAFLD and T2DM, regulating several inflammatory pathways ( table 1 ) [34] . In a human study, Larsen et al. [35] assessed the differences in gut microbiota composition in 36 men with and without T2DM. They found that in patients with T2DM, there was an increase in gram-negative bacteria belonging to the Bacteroidetes and Proteobacteria compared with the control group.
Two similar human studies showed significant correlations of specific gut bacteria and their genes with T2DM. The first was conducted in China; Qin et al. [36] mapped the metagenome sequences to known metagenome data sets. Their analyses indicated a decrease in butyrate-producing bacteria (such as Roseburia intestinalis ) and an increase in some opportunistic bacteria, as well as enrichment in pathways responsible for the oxidative stress in T2DM patients, compared with people without diabetes. Qin et al. [36] also introduced the concept of 'functional dysbiosis', explaining that there was an association with loss of certain functional bacteria such as butyrate-producing bacteria, rather than loss of specific gut microbiota directly related to T2DM. The second study was undertaken in European women with normal, impaired or poor glucose control. Karlsson et al. [37] used a metagenome-wide association study and developed a mathematical model based on metagenomics clusters, which allowed DNA that had not previously been sequenced to be included in the analysis that identified T2DM. Although Qin et al. [36] and Karlsson et al. [37] used different sequencing techniques to characterize the gut microbiota in T2DM patients, the results showed significant correlations of specific gut microbiome and T2DM. Both studies suggested that functional dysbiosis might reflect changes in intestinal environment that in turn favors the growth of certain gram-negative bacteria linked with T2DM. In addition, both the aforementioned studies showed lower concentrations of Roseburia intestinalis and Faecalibacterium prausnittzii and higher levels of Lactobacillus gasseri , Streptococcus mutans and Clostridiales in patients with T2DM.
Gut barrier integrity is another important physiological protection against endotoxins produced by gram-negative bacteria. Several studies have shown that high-fat diet reduces Bifidobacterium phylum with a secondary increase of LPS production and inflammatory activity [38] . In the presence of dysbiosis, there is an increased production of endotoxins from the Gram-negative bacteria that can damage the intestinal barrier. These endotoxins are then released in the blood stream causing a subclinical elevation in circulating levels of LPS [39] . This metabolic endotoxemia is characterized by a low-grade metabolic inflammation affecting different pathways linked with metabolic syndrome, NAFLD and insulin resistance. The degradation of the intestinal mucus layer can lead to intestinal inflammation and reduced function of Lcells and Paneth cells in the intestine. Akkermansia muciniphila is a mucin-degrading bacterium that resides in the mucus layer of the intestine. It is the dominant bacterium in the human intestine, representing 3-5% of the microbial community in healthy subjects. Although Akkermansia muciniphila is a gram-negative bacterium that contains LPS, the gut colonization of these bacteria has a protective role in metabolic endotoxemia [40] . There is an inverse correlation between the abundance of Akkermansia muciniphila and presence of obesity and T2DM.
In a study in mice, Everard et al. [41] demonstrated that the administration of live Akkermansia muciniphila restores the intestine mucus layer reducing the metabolic endotoxemia. Paneth cells are part of the epithelium in the small intestine. They produce several antimicrobial peptides for innate immunity such as the regenerating islet-derived III (RegIII-α RegIII-β and RegIII-γ) proteins which belong to the family of C-type lectins [42] . RegIII-γ has a specific antibacterial effect and administration of live Akkermansia muciniphila or Bifidobacterium breve effectively induces REGIII production and specifically the RegIII-γ production protecting the intestine barrier [43] . Moreover, Akkermansia muciniphila is associated with higher L-cell activity and consequent increased production of GLP-1 and GLP-2. Therefore, administration of Akkermansia muciniphila may improve glucose tolerance and decreased endogenous hepatic glucose production via an incretin-mediated effect. Recent evidence shows that one possible antidiabetic effect of metformin is the manipulation of the gut microbiota, favoring the growth of Akkermansia muciniphila and reducing gram-negative bacteria responsible for producing endotoxins [44] . Mounting evidence further suggests that one of the mechanisms of glucose-lowering effect of metformin is the modulation of gut microbiota. Metformin-induced effects in the intestine may also alter the bile acid pool to stimulate GLP-1 secretion and thereby affect risk of T2DM. The increase in the bile acid pool may then stimulate bile acid receptors on the L cell, causing an increase in GLP-1 secretion via mitochondrial oxidative phosphorylation and calcium influx. In addition, a study has shown that metformin protects against fructose-induced steatosis [45] . Spruss et al. [47] found that in mice with NAFLD, metformin reduces the translocation of gut bacteria and bacterial endotoxins, by protecting mice from the fructose-induced loss of tight junction proteins and zonula occludens 1 ( fig. 2 ) [46] .
Dysbiosis and Insulin Resistance
Both NAFLD and T2DM are characterized by insulin resistance and a state of chronic low-grade inflammation with endotoxemia, abnormal expression and production of hepatokines, interleukins and adipokines. Insulin resistance is caused by several factors such as lifestyle, nutritional habits, genetic determinants and ectopic lipid accumulation in the liver and muscles. Recent evidence shows that dysbiosis may also influence insulin resistance [48] . Interestingly, there is an increasing body of scholarship showing that a state of chronic inflammation and a pathological activation of the innate immune system causing an increased production of cytokines and/or adipokines may affect the regulation of insulin action [49] .
The physiological effect of insulin begins with the activation of the insulin receptor (IR) tyrosine kinase, which in turn promotes tyrosine kinase phosphorylation of IR substrates (IRS-1 and IRS-2). Phosphorylation of IRS-1 and IRS-2 activate phosphatidylinositol-3-OH kinase, which increases serine phosphorylation of Akt. The insulin signaling pathway may be disrupted by several mechanisms associated with, on one hand, metabolic inflammation as a consequence of LPS and endotoxin production, and, on the other, increased level of diacylglycerols (DAGs) and ceramides with a high-fat diet. The disruption of insulin signaling occurs via serine phosphorylation of IRS and decreased tyrosine phosphorylation of IRS. Circulating LPS or bacterial endotoxins stimulates inflammatory cytokine production and increases the activation of toll-like receptor (TLR) 2 and 4. The activation of TLRs increases the expression of several cytokines such as TNF-α and IL-6 involved in insulin signaling. c-Jun amino-terminal kinase (JNK) and the inhibitor of nuclear factor-κB kinase-β (IKK-β) are activated upon the exposure to cytokines such as TNF-α and IL-6, FFAs and endoplasmic reticulum stress [50] . The activation of the liver-specific JNK promotes hepatic steatosis associated with impaired expression of liver key lipogenic enzymes and impairs insulin signaling via serine phosphorylation of IRS1. The activation of IKK reduces the phosphorylation of Akt2 and increases ceramide synthesis. The impaired phosphorylation of Akt2 reduces insulin action and insulin suppression of hepatic gluconeogenesis [48] . Scorletti Within hepatocytes, long-chain fatty acids are esterified with glycerol-3-phosphate (derived from glycolysis) to form mono-acylglycerols, DAG and tri-acylglycerols. Lipid synthesis may increase production of intermediate lipids, such as DAG, di-palmitoyl phosphatidic acid and other lipid products, such as ceramides. The increased production of these lipid products (particularly DAGs) is very important in causing 'resistance' within the hepatic insulin signaling pathway [51] , promoting hepatic inflammation and increasing risk of progressive liver disease that occurs with NASH. Ceramide accumulation in the liver leads to an impairment of insulin action reducing Akt2 activation and to the activation of the protein kinase C (PKC)-ζ isoform. In addition, the increased levels of DAG in the liver can contribute to PKCε activation and translocation to the cell membrane, which results in inhibition of insulin signaling via inhibition of IR kinase activity. Gut microbiota can play a significant role in DAG production. Gut dysbiosis can lower intestinal pH and increase the production of secondary bile acids. The combination of low pH (<7) and secondary bile acids (mainly deoxycholic acid) favors the degradation of phosphatidylcholine by bacteria expressing phospholipase C (e.g., C. bifermentans and E. coli ) resulting in an increased DAG production and promoting hepatic inflammation, liver fat accumulation and impaired insulin signaling. There is also evidence that increased production of secondary bile acids by the gut bacteria may activate PKC thus impairing insulin signaling [52] .
Conclusions
Currently, there are limited human studies describing the association between gut microbiota, T2DM and NAFLD. In patients with NAFLD, there is clear evidence that diet can cause specific changes in the gut microbiota, which affect the aforementioned association. By contrast, there are very limited data describing NAFLD-specific changes in gut microbiota that are independent of diet and obesity. Some mechanisms that are relative to a puta- tive link between dysbiosis, T2DM and NAFLD may include increased intestinal permeability, low grade inflammation with endotoxemia, changes in the production of SCFAs with reduction of butyrate producing bacteria, alterations in choline metabolism and/or effects on the secretion of gut hormones such as GLP-1 and GLP-2. The similitude between bacteria that cause NAFLD and bacteria that cause T2DM could be the key to understanding the triangular relationship between dysbiosis and T2DM and NAFLD. These interactions are still poorly understood, although metagenomic studies have provided an enormous amount of data concerning the characterization of microbiota from different parts of the host's body in different conditions. High quality research clinical trials are needed to test whether improving dysbiosis ameliorates NAFLD and T2DM. Moreover, the newly described effects of metformin treatment on gut microbiota require further investigation to broaden our understanding of the molecular mechanisms of metformin action on the intestinal bacteria and to comprehend fully the dysbiotic changes in people with T2DM.
Finally, clinical research trials are urgently needed to test whether pre-probiotics or synbiotics have a beneficial effect on the gut microbiota of patients with NAFLD and T2DM.
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